Media Contact:
Nancy Pecota
Chief Financial Officer
Assistant: Rita Mateo
Phone: 510-265-9370
E-mail: investor@aradigm.com

Latest News

Aradigm Receives FDA Clearance for Clinical Trial of Inhaled Liposomal Ciprofloxacin in Pediatric Patients With Cystic Fibrosis
[05MAY10]

Aradigm Completes Enrollment and Doses Last Patient in Long Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
[25MAR10]

Aradigm Announces Fourth Quarter 2009 and Full Year Financial Results
[23MAR10]

Aradigm Doses First Patient in Its Second Phase 2b Clinical Trial of Inhaled Liposomal Ciprofloxacin in Bronchiectasis Patients
[23FEB10]

Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale of SUMAVEL* DosePro*
[04FEB10]

Aradigm to Present at Biotech Showcase 2010 on January 12
[06JAN10]

Aradigm to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
[10DEC09]

Aradigm Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
[16NOV09]

Aradigm Announces Third Quarter 2009 Financial Results
[14SEP09]

Aradigm to Present at the 8th Annual BIO Investor Forum on October 28
[22OCT09]

Aradigm Presents Data Demonstrating Significant Antibacterial Concentrations and Effects in Non-Cystic Fibrosis Bronchiectasis Patients Following Administration of its Once-Daily Inhaled Liposomal Ciprofloxacin
[14SEP09]

Aradigm Announces Second Quarter 2009 Financial Results
[06AUG09]

Aradigm Receives Orphan Drug Designation for Inhaled Liposomal Ciprofloxacin to Treat Cystic Fibrosis in Europe
[05AUG09]

Zogenix Announces Exclusive Co-Promotion Agreement in U.S. for Sumavel(TM) DosePro(TM)
[04AUG09]

Aradigm Receives FDA Clearance for Phase IIb Clinical Trial of Inhaled Liposomal Ciprofloxacin to Treat Bronchiectasis
[23JUL09]

Zogenix Obtains Approval in U.S. for Sumavel(TM) DosePro(TM)
[16JUN09]

Upcoming Events
For a listing of Upcoming Events click here.